Compare KRNY & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRNY | VSTM |
|---|---|---|
| Founded | 1884 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.6M | 470.7M |
| IPO Year | 2014 | 2011 |
| Metric | KRNY | VSTM |
|---|---|---|
| Price | $7.31 | $5.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.00 | ★ $15.00 |
| AVG Volume (30 Days) | 265.2K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-18-2026 |
| Dividend Yield | ★ 5.99% | N/A |
| EPS Growth | ★ 130.22 | 17.49 |
| EPS | ★ 0.30 | N/A |
| Revenue | $2,580,000.00 | ★ $30,914,000.00 |
| Revenue This Year | $3.89 | $254.18 |
| Revenue Next Year | $17.52 | $99.39 |
| P/E Ratio | $24.47 | ★ N/A |
| Revenue Growth | 36.00 | ★ 209.14 |
| 52 Week Low | $5.45 | $4.01 |
| 52 Week High | $8.50 | $11.25 |
| Indicator | KRNY | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 43.52 |
| Support Level | $6.30 | $5.56 |
| Resistance Level | $8.42 | $6.91 |
| Average True Range (ATR) | 0.26 | 0.33 |
| MACD | -0.07 | 0.08 |
| Stochastic Oscillator | 12.94 | 31.86 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.